Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

Br J Haematol. 2018 Mar;180(5):757-760. doi: 10.1111/bjh.14449. Epub 2016 Dec 16.
No abstract available

Keywords: Hodgkin lymphoma; antibody-drug conjugate; autologous stem cell transplant; monoclonal antibodies; refractory disease.

Publication types

  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bendamustine Hydrochloride / administration & dosage
  • Brentuximab Vedotin
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Immunoconjugates / administration & dosage
  • Male
  • Middle Aged
  • Treatment Outcome
  • Young Adult

Substances

  • Immunoconjugates
  • Brentuximab Vedotin
  • Bendamustine Hydrochloride